Akebia Therapeutics(AKBA)
$0.47-0.02 (-4.82%)
AKBA
Akebia Therapeutics financials statements
$0.47
At close:-0.02 (-4.82%)
Want to see AKBA full AI Analyst Report?
Akebia Therapeutics (AKBA) Ratios
1,689 Followers
Akebia Therapeutics Ratios
AKBA's free cash flow for Q3 2026 was $1.63M. For the 2026 fiscal year, AKBA's free cash flow was decreased by $-706.00K and operating cash flow was $2.33M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.13 | 1.41 | 1.18 | 1.43 | 1.04 |
| Quick Ratio | 1.04 | 1.21 | 1.03 | 1.26 | 0.90 |
| Cash Ratio | 1.13 | 0.64 | 0.43 | 0.70 | 0.57 |
| Solvency Ratio | -0.01 | -0.12 | -0.05 | -0.16 | -0.54 |
| Operating Cash Flow Ratio | 0.42 | -0.50 | -0.23 | -0.56 | -0.97 |
| Short-Term Operating Cash Flow Coverage | 1.70 | -9.43 | -1.20 | -2.29 | -2.59 |
| Net Current Asset Value | $ -159.11M | $ -156.02M | $ -154.14M | $ -165.64M | $ -184.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.57 | 0.86 | 0.43 | 0.28 | 0.26 |
| Debt-to-Equity Ratio | 6.63 | -3.84 | -3.41 | 19.08 | 1.84 |
| Debt-to-Capital Ratio | 0.87 | 1.35 | 1.42 | 0.95 | 0.65 |
| Long-Term Debt-to-Capital Ratio | 0.84 | 1.39 | 1.75 | 0.87 | 0.00 |
| Financial Leverage Ratio | 11.55 | -4.49 | -7.90 | 68.08 | 7.15 |
| Debt Service Coverage Ratio | 0.31 | -0.61 | -0.32 | 0.06 | -1.62 |
| Interest Coverage Ratio | 0.97 | -2.78 | -7.67 | -5.15 | -13.27 |
| Debt to Market Cap | 0.52 | 0.45 | 0.39 | 0.63 | 0.26 |
| Interest Debt Per Share | 0.94 | 0.98 | 0.59 | 0.63 | 0.94 |
| Net Debt to EBITDA | 1.45 | -9.97 | -7.41 | 3.05 | 0.07 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.29% | 60.56% | 61.90% | 92.31% | 61.50% |
| EBIT Margin | 8.66% | -31.98% | -23.58% | -11.84% | -107.67% |
| EBITDA Margin | 9.20% | -8.57% | -4.25% | 1.04% | -89.73% |
| Operating Profit Margin | 9.95% | -31.51% | -23.77% | -27.62% | -124.97% |
| Pretax Profit Margin | -1.58% | -43.33% | -26.68% | -32.22% | -133.25% |
| Net Profit Margin | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% |
| Continuous Operations Profit Margin | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% |
| Net Income Per EBT | 143.64% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | -15.83% | 137.52% | 112.26% | 116.65% | 106.62% |
| Return on Assets (ROA) | -1.42% | -31.45% | -21.48% | -26.46% | -53.28% |
| Return on Equity (ROE) | -16.39% | 141.12% | 169.78% | -1801.64% | -381.07% |
| Return on Capital Employed (ROCE) | 11.00% | -36.11% | -32.61% | -35.66% | -98.59% |
| Return on Invested Capital (ROIC) | 9.26% | -33.77% | -27.89% | -30.68% | -71.36% |
| Return on Tangible Assets | -1.68% | -42.94% | -35.42% | -41.89% | -77.87% |
| Earnings Yield | -1.29% | -17.32% | -22.34% | -89.34% | -75.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.02 | 4.66 | 4.95 | 7.26 | 4.10 |
| Payables Turnover | 1.86 | 4.16 | 5.07 | 1.25 | 2.43 |
| Inventory Turnover | 2.53 | 3.89 | 4.73 | 1.04 | 2.22 |
| Fixed Asset Turnover | 0.00 | 15.38 | 12.13 | 8.51 | 5.21 |
| Asset Turnover | 0.63 | 0.73 | 0.81 | 0.82 | 0.40 |
| Working Capital Turnover Ratio | 8.62 | 6.26 | 5.27 | 8.90 | 2.18 |
| Cash Conversion Cycle | 21.11 | 84.46 | 78.88 | 107.82 | 102.57 |
| Days of Sales Outstanding | 72.68 | 78.31 | 73.69 | 50.27 | 88.95 |
| Days of Inventory Outstanding | 144.38 | 93.84 | 77.24 | 349.94 | 164.05 |
| Days of Payables Outstanding | 195.95 | 87.70 | 72.04 | 292.39 | 150.44 |
| Operating Cycle | 217.06 | 172.16 | 150.92 | 400.21 | 253.01 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.26 | -0.19 | -0.12 | -0.40 | -1.52 |
| Free Cash Flow Per Share | 0.26 | -0.19 | -0.12 | -0.40 | -1.52 |
| Dividend Paid and CapEx Coverage Ratio | 233.65 | -1232.09 | 0.00 | -641.70 | -4287.54 |
| Capital Expenditure Coverage Ratio | 233.65 | -1232.09 | 0.00 | -641.70 | -4287.54 |
| Operating Cash Flow Coverage Ratio | 0.31 | -0.22 | -0.22 | -0.73 | -1.86 |
| Operating Cash Flow to Sales Ratio | 0.29 | -0.25 | -0.12 | -0.25 | -1.20 |
| Free Cash Flow Yield | 16.35% | -10.15% | -10.06% | -69.47% | -67.46% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -77.40 | -5.76 | -4.48 | -1.12 | -1.33 |
| Price-to-Sales (P/S) Ratio | 1.75 | 2.50 | 1.19 | 0.36 | 1.77 |
| Price-to-Book (P/B) Ratio | 12.70 | -8.15 | -7.60 | 20.17 | 5.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.12 | -9.85 | -9.94 | -1.44 | -1.48 |
| Price-to-Operating Cash Flow Ratio | 6.09 | -9.86 | -9.94 | -1.44 | -1.48 |
| Price-to-Earnings Growth (PEG) Ratio | 0.83 | -0.32 | 0.09 | 0.02 | 0.03 |
| Enterprise Value Multiple | 20.50 | -39.19 | -35.53 | 37.56 | -1.90 |
| Enterprise Value | 445.48M | 537.66M | 293.71M | 114.78M | 361.29M |
| EV to EBITDA | 20.50 | -39.19 | -35.53 | 37.56 | -1.90 |
| EV to Sales | 1.89 | 3.36 | 1.51 | 0.39 | 1.71 |
| EV to Free Cash Flow | 6.58 | -13.21 | -12.56 | -1.57 | -1.43 |
| EV to Operating Cash Flow | 6.55 | -13.22 | -12.56 | -1.57 | -1.43 |
| Tangible Book Value Per Share | -0.10 | -0.51 | -0.67 | -0.69 | -0.56 |
| Shareholders’ Equity Per Share | 0.13 | -0.23 | -0.16 | 0.03 | 0.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.44 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.92 | 0.76 | 1.04 | 1.60 | 1.28 |
| Net Income Per Share | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| Tax Burden | 1.44 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -0.18 | 1.36 | 1.13 | 2.72 | 1.24 |
| Research & Development to Revenue | 0.26 | 0.24 | 0.32 | 0.57 | 0.70 |
| SG&A to Revenue | 0.46 | 0.67 | 0.00 | 0.45 | 0.78 |
| Stock-Based Compensation to Revenue | 0.05 | 0.05 | 0.05 | 0.06 | 0.00 |
| Income Quality | -12.72 | 0.59 | 0.45 | 0.79 | 0.90 |
Currency in USD

